Related references
Note: Only part of the references are listed.Pembrolizumab Plus Chemotherapy in Squamous Non Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study
Silvia Novello et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
Marina C. Garassino et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
L. E. Hendriks et al.
ANNALS OF ONCOLOGY (2023)
Tumour-infiltrating lymphocytes: from prognosis to treatment selection
Koen Brummel et al.
BRITISH JOURNAL OF CANCER (2023)
Multiplex Immunohistochemistry and Immunofluorescence: A Practical Update for Pathologists
Paul W. Harms et al.
MODERN PATHOLOGY (2023)
Cancer statistics, 2022
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2022)
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
Aaron C. Tan et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
First-Line Immunotherapy for Non-Small-Cell Lung Cancer
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio
Jeng-Shiuan Tsai et al.
PHARMACEUTICALS (2022)
Platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios are associated with the efficacy of immunotherapy in stage III/IV non-small cell lung cancer
Xiaojuan Lu et al.
ONCOLOGY LETTERS (2022)
Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study
Giuseppe L. Banna et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2022)
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
Luis Paz-Ares et al.
LANCET ONCOLOGY (2021)
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
Ahmet Sezer et al.
LANCET (2021)
Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021,-189, and-407
Steven F. Powell et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy
Tianyu Tang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
Roy S. Herbst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer
Laura Mezquita et al.
JAMA ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer
Po-Lan Su et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy
Katherine A. Scilla et al.
ONCOLOGIST (2017)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Clinical significance of preoperative neutrophil-lymphocyte vs platelet-lymphocyte ratio in primary operable patients with non-small cell lung cancer
Hua Zhang et al.
AMERICAN JOURNAL OF SURGERY (2015)
Prognostic Significance of Preoperative Neutrophil-Lymphocyte Ratios in Patients with Stage I Non-small Cell Lung Cancer After Complete Resection
Yusuke Takahashi et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
Arnoud J. Templeton et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Response Criteria in Oncologic Imaging: Review of Traditional and New Criteria
Temel Tirkes et al.
RADIOGRAPHICS (2013)
Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer
Khaled M. Sarraf et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2009)
Cancer-related inflammation
Alberto Mantovani et al.
NATURE (2008)
Cancer immunoediting from immune surveillance to immune escape
Ryungsa Kim et al.
IMMUNOLOGY (2007)